Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AMG 397 + Azacitidine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 397||AMG-397|AMG397|Murizatoclax||MCL1 Inhibitor 18||AMG 397 is a small molecule inhibitor of MCL1 that selectively disrupts the interaction with members of the Bcl2 family, potentially resulting in increased cellular apoptosis, decreased cell viability, and reduced tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6218).|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03465540||Phase I||AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397||Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies||Terminated||USA | ITA | FRA||3|